Related Experiment Video
Updated: Aug 9, 2026
Efficient and Scalable Production of Full-length Human Huntingtin Variants in Mammalian Cells using a Transient Expression System
Published on: December 10, 2021
The association of CAG repeat length with clinical progression in Huntington disease
A Rosenblatt1, K-Y Liang, H Zhou
1Department of Psychiatry, Johns Hopkins University School of Medicine, Baltimore, MD, USA. arosenba@jhmi.edu
Insights
The size of the CAG expansion in Huntington disease (HD) influences clinical progression rates. Shorter CAG expansions are linked to a better prognosis, which is important for analyzing clinical trials.
Area of Science:
- Neuroscience
- Genetics
- Neurology
Background:
- Huntington disease (HD) is a progressive neurodegenerative disorder.
- The CAG repeat expansion in the HTT gene is the primary cause of HD.
- Understanding factors influencing disease progression is crucial for patient management and therapeutic development.
Purpose of the Study:
- To investigate the relationship between CAG expansion size and the rate of clinical progression in Huntington disease.
- To determine if CAG repeat length impacts various measures of disease severity and functional decline.
Main Methods:
- Analysis of 3,402 examinations from 512 Huntington disease subjects with a mean follow-up of 6.74 years.
- Utilized the Quantified Neurological Examination, including Motor Impairment and Chorea Scores, Mini-Mental State Examination, and HD Activities of Daily Living (ADL) Scale.
- Employed a Random Effects Model to assess the association between CAG length and disease progression rates.
Main Results:
- CAG repeat length was significantly associated with the progression rate of most clinical measures, excluding chorea and ADL scores.
- A significant interaction between CAG length and disease duration was observed for most measures.
- Data suggested that individuals with shorter CAG expansions may experience a more favorable late-stage disease course.
Conclusions:
- CAG repeat length exerts a small but potentially clinically significant effect on Huntington disease progression over time.
- Individuals with shorter CAG repeat expansions generally exhibit a better prognosis.
- These findings have implications for the analysis and design of clinical trials for Huntington disease.
Objective:
To determine whether the rate of clinical progression in Huntington disease (HD) is influenced by the size of the CAG expansion.
Methods:
The dataset consisted of 3,402 examinations of 512 subjects seen through the Baltimore Huntington's Disease Center. Subjects were seen for a mean of 6.64 visits, with mean follow-up of 6.74 years. Subjects were administered the Quantified Neurological Examination, with its subsets the Motor Impairment and Chorea Scores, the Mini-Mental State Examination, and the HD Activities of Daily Living (ADL) Scale.
Results:
In an analysis based on the Random Effects Model, CAG length was significantly associated with the rate of progression of all measures except chorea and ADL. There was a significant interaction term between CAG length and disease duration for all measures except chorea. Further graphical exploration of the data supported these linear models and suggested that subjects at the low end of the expanded CAG repeat range may experience a more benign late course.
Conclusions:
CAG repeat length has a small effect on rate of progression that may be clinically important over time. Individuals with the shortest expansions appear to have the best prognosis. These effects of the CAG length may be relevant in the analysis of clinical trials.
Related Concept Videos
01:21Huntington Disease l: Introduction
01:11Genome-wide Association Studies-GWAS
GWAS does not require the identification of the target gene involved in...
01:11Genetic Lingo
01:29Cardiomyopathy III: Hypertrophic Cardiomyopathy